An interventional study of Breakfast meal challenge with tonic drink and Breakfast meal challenge with placebo drink in Overweight or Obese Adults, sponsored by Australian Catholic University. Completed at 1 site in Australia. Open to participants aged 30 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Australian Catholic University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Overweight with a site in Australia — 35 open to participants now, 45 under way, 22 of them phase 3. Overweight · Australia.
Among the 83 studies in Overweight with a site in Australia, this one is the 77th largest by enrollment of the 79 interventional ones that give a count, is one of 16 that started in 2025, is one of 8 with no phase, and was the 43rd registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →35 of the 83 studies in Overweight with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Australia, United States, Canada and 2 more countries
Ages 18–99
Verdiva Bio Dev Limited · Sites in Australia
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 30 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 20 · Phase 3 27 · Phase 4 3
First in 2002; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 209 across the 79 interventional studies, 2,120 across the 4 observational. Of the 34 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 83 have an industry lead sponsor. The 10 most frequent:
Australian Catholic University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Australian Catholic University has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
16 of the studies in Overweight with a site in Australia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07532655CSPC ZhongQi Pharmaceutical Technology Co., Ltd.A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants | 2027-01-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 83 studies in Overweight with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomised, double blinded, placebo-controlled crossover design clinical trial conducted at the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with overweight/ obesity. This study will measure the postprandial glucose and hormone responses to a high-carbohydrate meal with/ without a liquid tonic drink.
Twenty individuals living with overweight/ obesity will be invited to attend the university laboratories on 2 separate occasions to participate in a postprandial (meal) challenge. Participants will consume the same high-carbohydrate meal on each visit, with or without a liquid tonic drink. This will be a cross-over design study, where participants will consume a placebo drink on the alternate visit. Participants will remain in the laboratory for 3-hours following the meal with a venous cannula in place, and have blood samples taken at regular timepoints. Blood samples will be analysed for glucose and appetite hormones. Participants will also wear a continuous glucose monitor throughout the period which encapsulates both study trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive the tonic drink on their first postprandial challenge
Other: Breakfast meal challenge with tonic drink
This arm will receive the placebo drink on their first postprandial challenge
Other: Breakfast meal challenge with placebo drink
High-carbohydrate containing breakfast meal with the addition of the tonic drink
High-carbohydrate containing breakfast meal with the addition of the placebo drink
3-hour postprandial glucose incremental area under the curve
Venous glucose concentrations measured over the 3 hour period following consumption of the breakfast meal and tonic drink/ placebo, and calculated using the trapezoid method, with T0 concentration as baseline
Time frame: 3 hours
3-hour postprandial insulin incremental area under the curve
Venous insulin concentrations measured over the 3 hour period following consumption of the breakfast meal and tonic drink/ placebo, and calculated using the trapezoid method, with T0 concentration as baseline
Time frame: 3-hours
3-hour interstitial postprandial glucose incremental area under the curve
The interstitial glucose levels observed for the 3 hours following consumption of the breakfast meal and tonic drink/placebo using continuous glucose monitors
Time frame: 3 hours
Matsuda index (Marker of whole-body postprandial insulin sensitivity)
This marker takes into account the 3- hour postprandial venous blood glucose and insulin measurements observed
Time frame: 3 hours
Venous blood C-peptide responses
3-hour postprandial C-peptide responses measured in venous blood as a marker of insulin secretion
Time frame: 3 hours
Venous blood insulin to glucagon ratio's at baseline (T0) and 30 minutes (T30)
Ratio of venous blood insulin to glucagon at baseline and 30 minutes (T0, T30) as a marker of hepatic glucose production.
Time frame: 30 minutes
Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Supporting information: Study protocol
Access criteria: Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 5 months is below that.
Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian Catholic University